Federated Hermes, Inc. Ambrx Biopharma Inc. Transaction History

Federated Hermes, Inc.

  • $41.2 Billion
  • Q2 2024

Shares

1 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2023

Nov 13, 2023
BUY
$9.3 - $16.6 $22.3 Million - $39.8 Million
2,395,867 New
2,395,867 $27.6 Million

Others Institutions Holding AMAM

# of Institutions
2
Shares Held
31.2K
Call Options Held
0
Put Options Held
0
View Full List

About Ambrx Biopharma Inc.

AMAM Quotes by TradingView
  • Ticker AMAM
  • Exchange NYSE
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 38,618,400
  • Market Cap $1.08B
  • Description
  • Ambrx Biopharma Inc., a clinical-stage biologics company, discovers and develops engineered precision biologics using its proprietary expanded genetic code technology platform. Its lead product candidate is ARX788, an anti-HER2 antibody-drug conjugate (ADC), which is investigated in various clinical trials for the treatment of breast cancer, gas...
More about AMAM
Track This Portfolio

Track Federated Hermes, Inc. Portfolio

Follow Federated Hermes, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Federated Hermes, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Federated Hermes, Inc. with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email